Bristol-Myers Squibb Company (BMY, Financial), Annaly Capital Management Inc. (NLY, Financial), Newell Brands Inc. (NWL, Financial) and Mylan NV (MYL, Financial) have declined to their three-year lows.
Bristol-Myers Squibb Company (BMY, Financial) declined to $45.57
The prices of CVS Health Corp (CVS) shares have declined to $52.81, which is only 2.0% above the 3-year low of $51.77.
Bristol-Myers Squibb Company is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis, and HIV.
Bristol-Myers Squibb Company has a market cap of $74.4 billion; its shares were traded around $45.57 with a P/E ratio of 15.02 and P/S ratio of 3.32. The trailing 12-month dividend yield of Bristol-Myers Squibb Company stocks is 3.53%. The forward dividend yield of Bristol-Myers Squibb Company stocks is 3.56%. Bristol-Myers Squibb Company had an annual average earnings growth of 18.40% over the past 5 years.
On April 12 Bristol-Myers Squibb Company announced that its shareholders have voted to approve the issuance of shares of the company’s common stock in connection with the company’s pending merger with Celgene Corporation at the special meeting of stockholders. More than 75% of the shares voted at the meeting were in favor of the merger agreement.
Annaly Capital Management Inc. (NLY, Financial) declined to $10.03
The prices of Annaly Capital Management Inc. (NLY, Financial) shares have declined to $10.03, which is only 4.6% above the 3-year low of $9.57.
Annaly Capital Management Inc. is an American mortgage real estate investment trust. The company borrows money via short term repurchase agreements and reinvests the proceeds in asset backed securities. The company generates profits from the net interest spread between the interest it earns from assets and borrowing costs.
Annaly Capital Management Inc. has a market cap of $14.47 billion; its shares were traded around $10.03 with a P/E ratio of 62.69 and P/S ratio of 18.64. The trailing 12-month dividend yield of Annaly Capital Management Inc. stocks is 8.98%. The forward dividend yield of Annaly Capital Management Inc. stocks is 11.94%.
On March 14 Annaly Capital Management Inc. announced that the company’s Board of Directors has declared the first quarter 2019 common stock cash dividend of $0.30 per common share. The dividend is payable on April 30 to shareholders of record at the close of business on March 29.
Newell Brands Inc. (NWL, Financial) declined to $15.39
The prices of Newell Brands Inc. (NWL, Financial) shares have declined to $15.39, which is only 4.2% above the 3-year low of $14.74.
Newell Brands Inc. is an American international marketer of consumer and commercial brands. Some the brands it has acquired include Rubbermaid, Contigo and Bubba, Coleman outdoor products, Diamond matches, Sharpie, and PaperMate.
Newell Brands Inc. has a market cap of $6.51 billion; its shares were traded around $15.39 with and P/S ratio of 0.74. The trailing 12-month dividend yield of Newell Brands Inc. stocks is 5.99%. The forward dividend yield of Newell Brands Inc. stocks is 5.99%. Newell Brands Inc. had an annual average earnings growth of 5.30% over the past 10 years.
On March 14 Newell Brands Inc. announced that Michael Polk, the company’s President and CEO since 2011, will retire from the company at the end of the second quarter of 2019. The Board of Directors has started a search process to identity the company’s next CEO and has retained Heidrick & Struggles, a global executive search firm, to assist in the process.
Mylan N.V. (MYL, Financial) declined to $26.97
The prices of Mylan N.V. (MYL, Financial) shares have declined to $26.97, which is only 3.6% above the 3-year low of $26.00.
Mylan N.V. is an international generic and specialty pharmaceuticals company headquartered in the United States. The company is the second largest generic and specialty pharmaceuticals company in the world and is a component of both the NASDAQ 100 and the S&P 500.
Mylan N.V. has a market cap of $13.92 billion; its shares were traded around $26.97 with a P/E ratio of 39.66 and P/S ratio of 1.22. Mylan N.V. had an annual average earnings growth of 7.80% over the past 10 years.
On March 18 Mylan N.V. announced that it is conducting a voluntary nationwide recall of two lots of Levoleucovorin Injection to the consumer level. The injection is being recalled due to the presence of copper salt particulate matter in the drug, which was discovered during a 12-month stability testing.
Disclosure: I do not own stock in any of the companies mentioned in the article.
